PHOTO
DUBAI: The Pharmaceutical Research & Manufacturers in the Gulf (PHRMAG) conducted its annual General Assembly meeting and announced its new Executive Committee for the 2021-2023 term.
In line with its commitment to promoting a more diverse and inclusive environment across the innovative biopharmaceutical industry, the new Executive Committee will include two female leaders - Gizem Akalin, Vice President and General Manager, GSK Gulf, and Lindsey Dietschi, Country Manager and Cluster Lead for Pfizer Gulf. Mohammad Aboubakr, General Manager, Gulf Countries, AbbVie, also joins the Executive Committee for the first time.
The General Assembly also welcomed its new member Servier, raising the membership to 25 globally leading healthcare companies operating in the Gulf region.
PHRMAG renewed its commitment to working in close collaboration with governments across the Gulf to help cope with the global COVID-19 pandemic and assist countries that aspire to build up their innovative life sciences and biopharmaceutical sectors. Specifically, PHRMAG and its members will continue to advance human health in the Gulf region through the discovery, development, manufacturing, and marketing of innovative treatments and cures.
Since 1995, PHRMAG has played a central role in the region representing the industry to officials in the healthcare sector amongst other stakeholders. PHRMAG has worked with governments to shape an attractive healthcare ecosystem encouraging innovative biopharmaceutical companies to invest, employ, and innovate.
PHRMAG’s primary mission is to support best practice and shape ecosystems that recognize and reward innovation. It enables providers and patients to enjoy access to cutting-edge, high-quality vaccines and medicines and works closely with sister trade and business associations, academics, think tanks, and thought leaders in the healthcare sector.
The general assembly concluded with a message of 'hope' and 'optimism,' emphasizing the industry's vital role in preventing, treating, and curing disease in the Gulf region.
About PHRMAG
The Pharmaceutical Research and Manufacturers in the Gulf (PHRMAG) represents 25 globally leading biopharmaceutical companies researching, developing, manufacturing, and marketing cutting-edge medicines and vaccines.
Based in Dubai, PHRMAG is devoted to two missions in the Gulf region: Advancing human health and strengthening the innovative biopharmaceutical sector.
Current members of the Executive Committee include Mohammed Ezz Eldin, Chairman of Novartis, Sameh Elfangari (AstraZeneca), Mohammad Aboubakr (AbbVie), Lindsey Dietschi (Pfizer), Gizem Akalin (GSK), Vishnu Kalra (J&J/Janssen), and Mazen Bachir (Abbott).
PHRMAG advocates policies and partnerships that support those missions, working with a wide range of stakeholders in Bahrain, Kuwait, Qatar, Oman, and the United Arab Emirates.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
